Literature DB >> 29760615

Stress, itch and quality of life in chronic urticaria females.

Alicja Ograczyk-Piotrowska1, Zofia Gerlicz-Kowalczuk1, Anna Pietrzak1, Anna M Zalewska-Janowska1.   

Abstract

INTRODUCTION: Chronic urticaria (CU) belongs to a group of psychodermatological disorders, thus stress can play a significant role in this dermatosis onset and/or exacerbation. On the other hand, the disease itself accompanied by itch, may be a source of distress and could worsen patients' quality of life (QoL). AIM: The first goal of our study was to compare stress intensity between CU subjects and the control group. The second aim was to investigate the relationships between disease-related parameters (CU severity, itch) and psychological variables (stress and QoL) in CU patients.
MATERIAL AND METHODS: Forty-six female patients with CU participated in our study. Thirty-three healthy females constituted a control group. The following methods were applied: Urticaria Activity Score (UAS), Itch Severity Evaluation Questionnaire, Visual analogue scale (VAS), Social Readjustment Rating Scale (SRRS) and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL).
RESULTS: Chronic urticaria patients demonstrated a significantly higher stress level in comparison to the control group (z = 2.699; p < 0.001). Regarding the total pruritus score, all CU-Q2oL dimensions were affected, except for subscale swelling/mental status. The strongest link was revealed between global itch and QoL subscale embarrassment (r = 0.51, p < 0.001). There were also statistically significant correlations between stress (VAS scale and SRRS) and QoL (all at least p < 0.05).Conclusions: Taking into account the significant pruritus contribution to QoL impairment, it would be worth employing itch-coping trainings in the CU group. As a consequence, feeling of self-control and self-efficacy could be enhanced, thus resulting in the well-being improvement.

Entities:  

Keywords:  chronic urticaria; embarrassment; itch; quality of life

Year:  2018        PMID: 29760615      PMCID: PMC5949545          DOI: 10.5114/ada.2018.75237

Source DB:  PubMed          Journal:  Postepy Dermatol Alergol        ISSN: 1642-395X            Impact factor:   1.837


Introduction

Chronic urticaria (CU) accounts for about 1–4% of the general population. Chronic urticaria diagnosis is established when the disease lasts for at least 6 weeks. Recurrent, temporary hives, accompanied by itch, are characteristic skin lesions in urticaria [1, 2]. Itch is described as a subjective and unpleasant sensation which results in scratching [3, 4]. Of importance, evaluation of CU intensity performed by Urticaria Activity Score (UAS) comprises also itch assessment [5]. Additionally, CU is also classified as a psychodermatological disorder. It was proved that factors, such as stress, can affect urticarial wheals onset and exacerbation [6, 7]. Emotional distress can also be related to itch intensity [8]. Stress is often experienced as anxiety which activates the autonomic nervous system. As a result, the itch threshold is lowered [9], so its intensity may be moderated not only by disease severity, but also by psychological factors. It was observed that individual perception of itch plays an important role in disease management [10]. What is more, strong focus on this unpleasant sensation can intensify itch and subsequently triggers scratching which is treated as the most automatic reaction of coping. On one hand, scratching allows to reduce inner tension, giving a sense of relief. On the other hand, however, intensive scratching can lead to itch-and-scratch vicious cycle formation. Such situation is associated with loss of control and feeling of inefficacy in itch management [10]. Of note, this unpleasant sensation is generally regarded as more burdensome for patients than pain [11]. It seems to be quite clear why itch is perceived as one of the strongest symptoms with a negative influence on patients’ quality of life (QoL) [10, 12]. Its intensity also plays an important role in worsening patients’ well-being [10, 12]. Moreover, itch exerts a negative impact on physical, cognitive, emotional and social functioning [7, 13–15]. It is worth emphasizing that evaluation of QoL in CU patients, by the most relevant tool, the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), tackles limits related to restricted diet, pressure-free clothes, anti-allergenic cosmetics and methods of coping with treatment side effects, such as somnolence after anti-histamine drugs or mass weight gain due to steroids employment [16-18].

Aim

The first goal of our study was to compare stress intensity between CU subjects and the control group. The second aim was to investigate the relationships between disease-related parameters (CU severity and itch) and psychological variables (stress and QoL) in CU patients.

Material and methods

The final study group was composed of 46 females (age mean: 44.6 ±14.2 years; range: 21–68 years) after excluding male patients due to gender disproportions (only 5 of them took part in our research). All participants did not suffer from any dermatological conditions, apart from chronic inducible urticaria: dermographism – 25 individuals, delayed pressure urticaria – 11 ones and cold urticarial – 10 participants. Almost one third of the group indicated a significant stress role in the course of their disease. The disease duration (median) was 11 ± 10.4 months (from 1.5 months to 25 years). In order to compare stress level results, we recruited the control group composed of 33 healthy females (age mean: 46.3 ±14.7; range: 18–78 years) who consulted dermatologists because of common warts and/or melanocytic nevi. They did not suffer from any other dermatological or chronic/infectious disorders. All participants were dermatological and allergological patients (out- and in-patients) of the region. The Bioethics Committee approval was obtained for the study and patients’ informed consent forms were collected. The research was performed in agreement with the Helsinki Declaration. The following methods were used in our study: authors’ questionnaire comprising socio-demographic data. Urticaria Activity Score 7 (UAS 7) – the tool to assess urticaria severity. The scale is recommended by the EAACI/GA2LEN/EDF guidelines. Urticaria Activity Score was estimated as the total result of two scores (range: 0–6): hives number (0–3) and itch intensity (0–3). The disease severity was examined over a period of 7 days to obtain weekly score (UAS 7) – range 1–42 points [5]. Itch Severity Evaluation Questionnaire (by Szepietowski and Reich, 2010) – the scale to assess global itch and its characteristic features concerning range (one location, several locations, generalized itch (range: 0–3)), intensity (regarding scratching necessity with or without excoriations (range: 0–5)), episodes duration (short episodes (less than 10 min), long episodes (longer than 10 min) or constant itch (range: 0–5)) and sleep disturbances as the consequence of itch (range: 0–6). The global result (from 3 to 19) is calculated as the sum of all the subscales points [11]. Visual analogue scale (VAS) – the scale was used to measure stress intensity (regarding last month). It is a 10 cm continuum (from “0” – no stress experienced to “10” – the most severe stress intensity). Results from 0 to 3 can be interpreted as mild, 3-6 as moderate, 7-9 as severe and 10 as very severe; Social Readjustment Rating Scale (SRRS) (by Holmes and Rahe, 1967) – the method to measure the stress level on the basis of the sum of stressful life events during last 12 months. The global result higher than 300 points can indicate the high life crisis level and the 80% risk of disease occurrence, 200–299 – moderate life crisis level and the 50% probability of illness onset and 150–199 – mild life crisis level and the 35% risk of disease development. The sum within the range of 0–150 points can be interpreted as lack of significant life problems [19]. The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) (Polish adaptation by Brzoza et al., 2011) – the specific tool to measure QoL in CU patients. It consists of 23 items regarding the disease influence on individual functioning. The tool comprises six subscales: itching, swelling/mental status, functioning, sleep, eating/limits and embarrassment. The results from subscales can be transferred for converted ones (range: 0–100) allowing for comparison between them. The higher the results, the more QoL is impaired [16, 20].

Statistical analysis

Statistica package (version 12) was employed for statistical analysis. Values such as: mean (M), median values (Me), minimum (min), maximum (max), standard deviation (SD), standard error of measurement (SEM) and percentiles (25–75%) are demonstrated. The criterion of normal distribution was not met by some variables, so non-parametric tests – Mann-Whitney U-test (z) and Spearman’s rank correlation test (r) were used. The statistical significance level was set at p < 0.05.

Results

Stress in studied groups

The results concerning stress were compared between the study and the control group. CU patients experienced more intensive stress regarding subjective perception (VAS scale, z test value = 2.699, p < 0.01). We did not observe any statistically significant difference between the studied groups regarding the number of difficult events in participants’ lives (SRRS scale, p > 0.05).

Disease severity, itch and quality of life

The variables regarding disease severity, itch and quality of life could be analyzed only in the CU patients group. The median UAS 7 result was 35 (range: 7–42; SEM = 1.40), which can be interpreted as the disease of severe intensity. Global itch results indicated its moderate level (mean: 8.00 ±4.15; range: 3–19). The majority of the group (48%) suffered from itch concerning several locations and itch with the demand of scratching without excoriations (n = 23; 50% of the patients). Short episodes of this unpleasant sensation were the most frequently reported (n = 23; 50% of CU participants). Itch-related sleep disturbances were regarded by 18 patients (39% of the group). Ten of them reported more than 3 awakenings during one night. The quality of life results (expressed as converted scores) are presented in Table 1. Of note, subscales itching and embarrassment were the most severely affected.
Table 1

Quality of life in the study group (CU-Q2oL subscales)

CU-Q2oLMeanMedian25–75% values
Itching60.2260.0040.00–70.00
Swelling/mental status49.3948.0036.00–60.00
Functioning41.4533.3420.00–56.67
Sleep51.6352.5030.00–70.00
Eating/limits49.6747.5030.00–60.00
Embarrassment62.6170.0040.00–80.00
Quality of life in the study group (CU-Q2oL subscales) Disease severity positively correlated with global itch score (r = 0.35, p < 0.05), itch intensity (r = 0.33, p < 0.05) and range (r = 0.33, p < 0.05). Regarding psychological parameters, higher CU activity was associated with a higher stress level (VAS scale – r = 0.31, p < 0.05; SRRS – r = 0.33, p < 0.05) and worse QoL (all dimensions). The strongest correlations were observed between disease severity and subscales itching (r = 0.61, p < 0.001) and functioning (r = 0.48, p < 0.05). Any further relations, thus between age, disease duration and psychological variables were not revealed (p > 0.05).

Stress, itch and quality of life – correlations

We did not note any statistically significant correlations between stress (both scales) and itch (and its features). Regarding the global itch score, all CU-Q2oL dimensions were affected, except for subscale swelling/mental status (results shown in Table 2).
Table 2

The correlations between itch and CU-Q2oL

CU-Q2oLItch characteristics
RangeIntensityFrequencyGlobal itch
Short itch episodesLong itch episodesConstant itch
rprprprprprp
Itching0.17> 0.050.22> 0.050.25> 0.050.24> 0.050.25> 0.050.44< 0.01
Swelling/mental status0.22> 0.050.24> 0.05–0.04> 0.050.07> 0.050.17> 0.050.28> 0.05
Functioning0.26> 0.050.19> 0.050.33< 0.050.24> 0.050.25> 0.050.45< 0.01
Sleep0.09> 0.050.33< 0.050.20> 0.050.31< 0.05–0.06> 0.050.35< 0.05
Eating/limits0.15> 0.050.29> 0.050.13> 0.050.18> 0.050.19> 0.050.42< 0.01
Embarrassment0.23> 0.050.44< 0.010.17> 0.050.18> 0.050.31< 0.050.51< 0.001

r – Spearman’s rank correlation, p – significance level.

The correlations between itch and CU-Q2oL r – Spearman’s rank correlation, p – significance level. We also observed statistically significant correlations between stress (VAS scale and SRRS) and QoL (results presented in Table 3).
Table 3

The correlations between stress and CU-Q2oL

CU-Q2oLStress (VAS)Stress (SRRS)
r p r p
Itching0.38< 0.010.28> 0.05
Swelling/mental status0.42< 0.010.46< 0.01
Functioning0.23> 0.050.26> 0.05
Sleep0.35< 0.050.35< 0.05
Eating/limits0.05> 0.050.36< 0.05
Embarrassment0.25> 0.050.33> 0.05

r – Spearman’s rank correlation, p – significance level.

The correlations between stress and CU-Q2oL r – Spearman’s rank correlation, p – significance level.

Discussion

Bearing in mind the aim of our study, the differences between CU patients and the control group were noted. Chronic urticaria individuals demonstrated higher levels of stress, but this difference between research groups, was limited only to the subjective perception of this phenomenon (VAS scale). What is worth emphasizing, the statistical correlation was lost (p > 0.05) when we compared the amount of stressful events in participants’ lives (the scale by Holmes and Rahe). So, the appraisal of the situations could be regarded as being of key relevance to the patients [21]. Additionally, some researchers reported that CU patients more often present specific personality traits, such as neuroticism [22, 23], which make them more sensitive to stress experience. As a consequence, patients could be more susceptible to CU relapses and exacerbations. This observation is consistent with literature data pointing to the role of emotional distress in the disease onset [6, 7, 24–26]. On the other hand, one’s experience of difficult emotions can be also perceived as a disease consequence. The latter was revealed by CU-Q2oL. In other words, the examined group of CU patients manifested worsened QoL. This observation is in agreement with literature data [16, 18, 27–30]. The above seems to be explained by an unpredictable course of CU, recurrent disease episodes and the location of skin lesions (on visible body parts). Exposed hives could cause embarrassment in social situations and lead to stigmatization. This phenomenon is well documented regarding other dermatoses, for example in psoriatics or in individuals suffering from atopic dermatitis [31, 32]. In our research, the QoL subscale embarrassment was most affected. Itch is the symptom strongly related to patients’ well-being. Such associations were also noted in other studies [10, 12, 15]. Itch (its global result) was associated with all domains of QoL, apart from subscale swelling/mental status. The strongest correlation was marked between its total score and embarrassment. It could be explained on the basis of patients’ reports indicating that itch leads directly to scratching which attracts negative attention of others and influence one’s social perception. As the consequence, patients could feel ashamed in public situations [17]. It was even noted that people suffering from contact dermatitis avoided social interactions due to their burdensome itch and the demand of scratching related to it [33, 34]. We could assume that such situations could lead to social interactions deficits in CU patients. Additionally, patients could pay their attentional focus to bodily sensations, what also enhances itch and scratching behaviour [35]. So, coping with it may become more difficult and could lead to belief of losing control over that symptom. Finally, feelings of helplessness can develop and be a source of worse QoL [10]. As for current study limitations, the number of the patients seems to be not large, but at this stage we were unable to extend the study. Furthermore, we did not take into account the significance of cognitive appraisal in perception of stressful situations and disease coping strategies. Both parameters could play a significant mediating role, providing more detailed explanation of stress, itch and QoL relations.

Conclusions

Taking into consideration the significant role of itch in QoL impairment in CU patients, it would be worth employing itch-coping trainings in this group. The effectiveness of such interventions is also reported in literature data [36]. Better management of this sensation could result in breaking the itch-and-scratch vicious cycle. As a consequence, feeling of self-control and self-efficacy could develop, thus leading to QoL improvement in CU patients.
  29 in total

1.  Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients.

Authors:  G Schmid-Ott; H W Kuensebeck; B Jaeger; T Werfel; K Frahm; J Ruitman; A Kapp; F Lamprecht
Journal:  Acta Derm Venereol       Date:  1999-11       Impact factor: 4.437

2.  Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis.

Authors:  Andrea W M Evers; Piet Duller; Elke M G J de Jong; Marisol E Otero; Christianne M Verhaak; Pieter G M van der Valk; Peter C M van de Kerkhof; Floris W Kraaimaat
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

3.  The Social Readjustment Rating Scale.

Authors:  T H Holmes; R H Rahe
Journal:  J Psychosom Res       Date:  1967-08       Impact factor: 3.006

4.  Investigation of dermatology life quality index and serum prolactin and serum dehydroepiandrosterone sulphate levels in patients with chronic urticaria.

Authors:  Derya Ucmak; Meltem Akkurt; Feyzullah Uçmak; Gülten Toprak; Gurbet Acar; Mustafa Arica
Journal:  Asian Pac J Allergy Immunol       Date:  2014-12       Impact factor: 2.310

5.  The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument.

Authors:  A W M Evers; P Duller; P C M van de Kerkhof; P G M van der Valk; E M G J de Jong; M J P Gerritsen; E Otero; E W M Verhoeven; C M Verhaak; F W Kraaimaat
Journal:  Br J Dermatol       Date:  2007-11-10       Impact factor: 9.302

6.  Cognitive, behavioral, and physiological reactivity to chronic itching: analogies to chronic pain.

Authors:  Lisette Verhoeven; Floris Kraaimaat; Piet Duller; Peter van de Kerkhof; Andrea Evers
Journal:  Int J Behav Med       Date:  2006

7.  The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings.

Authors:  A Młynek; M Magerl; M Hanna; S Lhachimi; I Baiardini; G W Canonica; Z Brzoza; A Kasperska-Zajac; B Rogala; A Zalewska-Janowska; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2009-06       Impact factor: 13.146

8.  Hostile personality characteristics, dysthymic states and neurotic symptoms in urticaria, psoriasis and alopecia.

Authors:  G C Lyketsos; J Stratigos; G Tawil; M Psaras; C G Lyketsos
Journal:  Psychother Psychosom       Date:  1985       Impact factor: 17.659

9.  Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria.

Authors:  Mine Ozkan; Serap Batmaz Oflaz; Nazmiye Kocaman; Ferhan Ozseker; Ash Gelincik; Suna Büyüköztürk; Sedat Ozkan; Bahattin Colakoğlu
Journal:  Ann Allergy Asthma Immunol       Date:  2007-07       Impact factor: 6.347

Review 10.  Urticaria: impact on quality of life and economic cost.

Authors:  Brigid F O'Donnell
Journal:  Immunol Allergy Clin North Am       Date:  2014-02       Impact factor: 3.479

View more
  4 in total

1.  Urticaria from the Neurodermatological Perspective: A Temporal Analysis of Urticaria and Cognition.

Authors:  Tagka A; George I Lambrou; Aikaterini Kyritsi; Styliani A Geronikolou; Electra Nikolaidou; Alexandra Katsarou; Argyro Chatziioannou; Alexandros Stratigos; Dimitris Rigopoulos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Role of Lactium™ in Psychodermatology: The CERTAIN Trial# on Patients with Acne Vulgaris.

Authors:  Amit Shivaji Kerure; Satish Udare; Chetan Vispute
Journal:  Dermatol Res Pract       Date:  2022-05-04

3.  The Burden on Cohabitants of Patients with Chronic Spontaneous Urticaria: A Cross-Sectional Study.

Authors:  Manuel Sánchez-Díaz; Maria-Carmen Salazar-Nievas; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

Review 4.  Itch and Psyche: Bilateral Associations.

Authors:  Radomir Reszke; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.